IRhythm Technologies to Report Second Quarter 2024 Financial Results on August 1, 2024
SAN FRANCISCO, July 18, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today
Med-tech and Healthcare Stocks With Upside During 2Q Earnings - Baird
The Analyst Verdict: IRhythm Technologies In The Eyes Of 5 Experts
5 analysts have shared their evaluations of iRhythm Technologies (NASDAQ:IRTC) during the recent three months, expressing a mix of bullish and bearish perspectives.The table below provides a concise
Truist Financial Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Announces Target Price $134
Truist Financial analyst Richard Newitter maintains $iRhythm Technologies(IRTC.US)$ with a buy rating, and sets the target price at $134.According to TipRanks data, the analyst has a success rate of 5
IRhythm Technologies Price Target Cut to $134.00/Share From $145.00 by Truist Securities
IRhythm Technologies Price Target Cut to $134.00/Share From $145.00 by Truist
IRhythm Technologies Is Maintained at Buy by Truist Securities
IRhythm Technologies Is Maintained at Buy by Truist
Truist Lowers Price Target on IRhythm Technologies to $134 From $145, Maintains Buy Rating
iRhythm Technologies (IRTC) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $115 to $165.
Express News | IRhythm Technologies Inc : Truist Securities Cuts Target Price to $134 From $145
IRhythm Technologies Price Target Cut to $130.00/Share From $135.00 by Morgan Stanley
IRhythm Technologies Price Target Cut to $130.00/Share From $135.00 by Morgan
IRhythm Technologies Is Maintained at Overweight by Morgan Stanley
IRhythm Technologies Is Maintained at Overweight by Morgan
Express News | IRhythm Tech Inc : Morgan Stanley Cuts Target Price to $130.00 From $135.00
Morgan Stanley Maintains IRhythm Technologies(IRTC.US) With Buy Rating, Raises Target Price to $130
Morgan Stanley analyst Kallum Titchmarsh maintains $iRhythm Technologies(IRTC.US)$ with a buy rating, and adjusts the target price from $125 to $130.According to TipRanks data, the analyst has a
Morgan Stanley Cuts Price Target on IRhythm Technologies to $130 From $135, Keeps Overweight Rating
iRhythm Technologies (IRTC) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $115 to $165.
Oppenheimer's Top SMID Ideas Within High-growth Themes
Despite Currently Being Unprofitable, IRhythm Technologies (NASDAQ:IRTC) Has Delivered a 57% Return to Shareholders Over 3 Years
By buying an index fund, you can roughly match the market return with ease. But many of us dare to dream of bigger returns, and build a portfolio ourselves. Just take a look at iRhythm Technologies,
Did Your Heart Skip a Beat? Your Wearable Knows. -- Barrons.com
By Bill Alpert The day is approaching when your wristwatch may send you to the hospital. The first portable electrocardiograph was an 85-pound backpack. Today, a 10-gram patch stuck on your chest ca
Heart Just Skip a Beat? Your Watch Already Knows.
Smart rings and smartwatches are providing consumers with reams of health information. Clinical device makers like DexCom needn't worry.
China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?
These mid-cap stocks were the best performers in the last week. Are they in your portfolio?Bilibili Inc. (NASDAQ:BILI) shares rose 23.32% following last week's release of 'San Guo: Mou Ding Tian Xia.'
Street Calls of the Week: Micron Downgrade, Upgrade for Kroger
IRhythm Gains as Wolfe Upgrades on Valuation